Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)Jihong Xu, W. Su, Chunmei Bai et al.|Annals of Oncology|2019Cited by 17